Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03434613
Recruitment Status : Completed
First Posted : February 15, 2018
Last Update Posted : March 16, 2020
Sponsor:
Information provided by (Responsible Party):
Yonsei University

Brief Summary:

To investigate the therapeutic effect of ezetimibe on nonalcoholic fatty liver disease, the effect of rosuvastatin 5mg monotherapy and rosuvastatin 5mg / ezetimibe 10mg combination therapy n patients with hyperlipidemia and fatty liver will be compared and analyzed.

This study included a total of 70 patients (35 per subgroup) for randomized controlled trials with prospective, open label, randomized, single-institution clinical trials.

The drug will be maintained for a total of six months. The primary endpoint is the difference of liver fat change measured by MRI-PDFF in colocalized regions of interest within nine liver segments between two groups.


Condition or disease Intervention/treatment Phase
Nonalcoholic Fatty Liver Disease Dyslipidemias Drug: Rosuvastatin Drug: Rosuvastatin/ezetimibe combination Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 64 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: This study will conduct to evaluate the efficacy of liver fat lowering and safety of rosuvastatin 5mg alone or in combination with rosuvastatin 5mg / ezetimibe 10mg for 6 months.
Masking: None (Open Label)
Masking Description: Open label
Primary Purpose: Treatment
Official Title: A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease
Actual Study Start Date : May 14, 2018
Actual Primary Completion Date : September 11, 2019
Actual Study Completion Date : September 11, 2019


Arm Intervention/treatment
Active Comparator: Rosuvastatin monotherapy
Rosuvastatin 5mg 1T daily for 6 months
Drug: Rosuvastatin
Rosuvastatin 5mg 1T daily for 6 months

Experimental: Rosuvastatin + ezetimibe combination therapy
Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months
Drug: Rosuvastatin/ezetimibe combination
Rosuvastatin 5mg / Ezetimibe 10mg combination 1T daily for 6 months




Primary Outcome Measures :
  1. liver fat change measured by MRI-PDFF in colocalized regions of interest within each of nine liver segments [ Time Frame: 6 months ]
    MRI is used to measure the fat fraction in 9 liver segments, and this test has been reported to be more sensitive than the biopsy-based steatosis grade assessment in confirming liver fat changes in previous studies


Secondary Outcome Measures :
  1. Liver fibrosis measured by MRE(magnetic resonance elastography) [ Time Frame: 6 months ]
    The secondary endpoint is to analyze the changes before and after drug administration for the following items: Liver fibrosis measured by MRE(magnetic resonance elastography)

  2. Change in hepatic steatosis index - controlled attenuation parameter (CAP) [ Time Frame: 6 months ]
  3. Change in hepatic fibrosis index - liver stiffness measurement (LSM) measured by transient liver elastography (Fibroscan®; Echosens, Paris, France) [ Time Frame: 6 months ]
  4. Changes in body weight (kg) before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  5. Changes in waist circumference (cm) before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  6. Changes in systolic & diastolic blood pressure (mmHg) before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  7. Changes in serum concentrations of insulin (µU/mL), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  8. Changes in serum concentrations of fasting glucose (mg/dL), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  9. Changes in serum concentrations of HbA1c (%), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  10. Change in insulin sensitivity determined by homeostatic model assessment insulin resistance (HOMA-IR) and beta cell function determined by HOMA-beta [ Time Frame: 6 months ]
  11. Changes in serum concentrations of free fatty acid (μEq/L), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  12. Changes in serum concentrations of platelet (×103/ μL), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  13. Changes in serum concentrations of alkaline phosphate (U/L) and gamma-GT(U/L), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  14. Changes in serum concentrations of total bilirubin (mg/dL), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  15. Changes in serum concentrations of liver enzymes (aspartate aminotransferase and alanine aminotransferase (IU/L)), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  16. Changes in serum lipids (total cholesterol, triglyceride, HDL cholesterol, and LDL cholesterol (mg/dL)), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  17. Changes in serum concentrations of CRP (mg/dL), before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  18. Changes in the level of liver injury markers including IL-1beta, IL-8, IL-18 (pg/mL) before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]
  19. Changes in plasminogen activator inhibitor-1 (ng/mL) in peripheral blood mononuclear cells, before and after the administration of rosuvastatin with/without ezetimibe [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women ages 19 and over, under 80 years of age
  • Patients diagnosed with fatty liver by abdominal ultrasonography or liver fibroscan. (In case of patients who were diagnosed fatty liver by liver scan, we will conduct abdominal ultrasonography for screening purposes)
  • In the Domestic Dyslipidemia Treatment Guideline, patients with hyperlipidemia A. LDL-C is more than 130mg / dL when there is less than 1 major risk factor B. LDL-C 100 mg / dL or more if there are two or more major risk factors C. High-risk patients with carotid stenosis> 50%, abdominal aortic aneurysm, and diabetes mellitus had LDL-C> 70 mg / dL

D. The main risk factors are as follows:

i. smoking ii. Hypertension - systolic blood pressure greater than 140 mmHg or diastolic blood pressure greater than 90 mmHg or antihypertensive iii. Low HDL cholesterol (<40 mg / dL) iv. Age - Male 45+, Female 55+ v. Family history of early onset coronary artery disease - Parents, siblings with a history of coronary artery disease in men under 55 and women under 65 vi. High HDL cholesterol (60 mg / dL) or more is regarded as a protective factor and one of the total risk factors is reduced

  • Even if it does not meet the criteria for hyperlipidemia, it is possible to select the subject when there is evidence of atherosclerosis on the test (carotid ultrasonography etc)
  • Those who already use statin as a treatment for hyperlipemia should participate after a washout period of 1-2 weeks.
  • Controlled diabetic patients (HbA1c ≤9.0%), no change in type of oral or injectable hypoglycemic agents for the last 12 weeks
  • Those who voluntarily agreed to participate in clinical trials after hearing the explanation of the clinical trial
  • Those who understand the content of the clinical trial and are able to participate in the trial by the end of the clinical trial

Exclusion Criteria:

  • Diabetic patients other than type 2 diabetes, including type 1 diabetes and gestational diabetes
  • Those who have a previous history of medication with ezetimibe or discontinuation due to side effects after medication
  • Patients who have had a history of discontinuation of statin therapy due to side effects after medication,
  • Unregulated diabetic patients (those who have changed the type of oral or injectable hypoglycemic agent within 12 weeks prior to Visit 1 or who have HbA1c> 9.0% at screening time (Visit 1)
  • patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma, and patients with a history of ketonic acidosis (within 6 months)
  • Those who use thiazolidinedione and SGLT2i drugs which can affect fatty liver as a diabetes treatment drug
  • Patients who meet the criteria for alcoholism in fatty liver disease (210 g / week for men in the last two years, 140 g / week for women)
  • Chronic liver disease (including hemochromatosis, liver cancer, autoimmune liver disease, Child-Pugh score> 7points, platelet <75,000mm2, prothrombin time> 16s), viral hepatitis -A, B,
  • People who take drugs that can cause fatty liver (amiodarone, methotrexate, tamoxifen, valproate, corticosteroids, etc.)
  • Patients who are allergic or hypersensitive to the drug or its constituents
  • Patients who were treated with oral or parenteral corticosteroids chronic (within consecutive 14 days) within 8 weeks before screening
  • Patients with genetic problems such as galactose intolerance, Lapp lactose dehydrogenase deficiency or glucose-galactose uptake disorder
  • Patients with malnutrition, starvation, weakness (including severe infections, pre- and post-operative trauma patients), pituitary dysfunction or adrenal insufficiency
  • Serum levels of alanine aminotransferase, aspartate aminotransferase or alkaline phosphatase are increased over 5-fold elevation of the normal range upper limit [ULN] or 5-fold elevation of the serum total bilirubin level. )
  • Currently taking medication for weight loss
  • Patients with a history of malignant tumors within the past 2 years or malignant tumors that are currently undergoing treatment or progression
  • Patients with a history of substance abuse or alcohol intoxication within 12 weeks
  • Human immunodeficiency virus (HIV)
  • Patients with severe infection, pre- and post-operative, and severe trauma
  • Patients with acute cardiovascular disease within 12 weeks (patients with unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass grafting, or coronary intervention)
  • Patients with renal failure, chronic renal disease (estimated glomerular filtration rate <60 mL / min / 1.73 m2)
  • Anemic patients with a Hb level of less than 10.5 g / dl
  • Surgical or medical conditions that may affect the absorption, distribution, metabolism and excretion of a drug, including, but not limited to, gastrectomy, gastroenterostomy, History of major gastrointestinal surgery such as small bowel resection, gastrointestinal bypass, gastrointestinal stapling, current active gastritis, gastrointestinal / rectal bleeding, active inflammatory bowel syndrome within the last 12 months, etc.
  • Pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03434613


Locations
Layout table for location information
Korea, Republic of
Yonsei University College of Medicine, Department of Internal Medicine, Division of Endocrinology, Severance Hospital, Diabetes center
Seoul, Korea, Republic of, 03722
Sponsors and Collaborators
Yonsei University
Publications:
Layout table for additonal information
Responsible Party: Yonsei University
ClinicalTrials.gov Identifier: NCT03434613    
Other Study ID Numbers: 4-2017-1168
First Posted: February 15, 2018    Key Record Dates
Last Update Posted: March 16, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Diseases
Fatty Liver
Non-alcoholic Fatty Liver Disease
Dyslipidemias
Hyperlipidemias
Hyperlipoproteinemias
Digestive System Diseases
Lipid Metabolism Disorders
Metabolic Diseases
Rosuvastatin Calcium
Ezetimibe
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors